Menée en Suède à partir de données portant sur 409 patients atteints d'un cancer de l'oesophage traité par oesophagectomie, cette étude analyse les facteurs associés à deux types de trajectoires de la fatigue, jusqu'à 5 ans après les traitements curatifs

Cancer-related fatigue trajectories up to 5 years after curative treatment for oesophageal cancer

Cheng, Zhao ; Johar, Asif ; Nilsson, Magnus ; Schandl, Anna ; Lagergren, Pernilla

Background: Whether cancer-related fatigue develops differently after curative-intended oesophageal cancer treatment and the related modifiable factors are unclear. Methods: This population-based and longitudinal cohort included 409 oesophageal cancer patients who underwent curative oesophagectomy in 2013–2020 in Sweden. The main outcome was cancer-related fatigue trajectories with measurements at 1, 1.5, 2, 2.5, 3, 4 and 5 years postoperatively by validated EORTC QLQ-FA12 questionnaire, and [...]

Menée à partir de données portant sur 1 506 patients ayant survécu à un cancer colorectal, cette étude de cohorte évalue l'association entre l'hématocrite et la présence d'une fatigue liée au cancer

Hematocrit is associated with cancer-related fatigue in colorectal cancer survivors: a longitudinal analysis

Kiebach, Joann ; de Vries-ten Have, Judith ; van Duijnhoven, Fränzel JB. ; Kok, Dieuwertje E. ; van Lanen, Anne-Sophie ; Kouwenhoven, Ewout A. ; de Wilt, Johannes HW ; Schrauwen, Ruud W M. ; Kampman, Ellen ; Winkels, Renate M. ; Wesselink, Evertine

Background: Cancer-related fatigue (CRF) is a frequent symptom in colorectal cancer survivors. It is unknown to what extent anemia may contribute to CRF in colorectal cancer survivors. This study aimed to investigate the association between hematocrit, as marker for anemia, and CRF among colorectal cancer survivors from diagnosis until two years thereafter. Methods: The study population included 1,506 newly diagnosed colorectal cancer survivors at any stage of disease from a prospective cohort [...]

Menée à partir de données portant sur 1 906 patients atteints d'un carcinome hépatocellulaire lié au virus de l'hépatite B ou C et ayant subi une résection hépatique, cette étude de cohorte analyse l'utilisation d'une thérapie antivirale et évalue l'effet de cette thérapie sur la survie globale à 10 ans

Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma

Daniel Q. Huang ; Joseph K. Hoang ; Rubayet Kamal ; Pei-Chien Tsai ; Hidenori Toyoda ; Ming-Lun Yeh ; Satoshi Yasuda ; Jennifer Leong ; Mayumi Maeda ; Chung-Feng Huang ; Dae Won Jun ; Masatoshi Ishigami ; Yasuhito Tanaka ; Haruki Uojima ; Eiichi Ogawa ; Hiroshi Abe ; Yao-Chun Hsu ; Cheng-Hao Tseng ; Manaf Alsudaney ; Ju Dong Yang ; Yoko Yoshimaru ; Takanori Suzuki ; Joanne K. Liu ; Charles Landis ; Chia-Yen Dai ; Jee-Fu Huang ; Wan-Long Chuang ; Myron Schwartz ; Yock Young Dan ; Carlos Esquivel ; Andrew Bonham ; Ming-Lung Yu ; Mindie H. Nguyen

Purpose: There are limited data on antiviral treatment utilization and its impact on long-term outcomes of hepatitis B virus (HBV)– and hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) after hepatic resection. We aimed to determine the utilization and impact of antivirals in HBV- and HCV-related HCC. Methods: This cohort study included 1,906 participants (1,054 HBV-related HCC and 852 HCV-related HCC) from 12 international sites. All participants had HBV- or HCV-related HCC and [...]

A l'aide de données de la littérature (159 revues, 2 611 études), cette étude cartographie les données probantes sur les facteurs de risque et les interventions concernant les maladies non transmissibles chez les enfants et les adolescents du monde entier

An evidence gap map of interventions for noncommunicable diseases and risk factors among children and adolescents

Salam, Rehana A. ; Khan, Maryam Hameed ; Meerza, Syed Saqlain Ali ; Das, Jai K. ; Lewis-Watts, Laura ; Bhutta, Zulfiqar A.

Substance misuse, obesity, mental health conditions, type 1 diabetes, cancers, and cardiovascular and chronic respiratory diseases together account for 41% of disability-adjusted life years linked to noncommunicable diseases (NCDs) among children and adolescents worldwide. However, the evidence on risk factors and interventions for this age group is scarce. Here we searched four databases to generate an evidence gap map of existing interventions and research gaps for these risk factors and [...]

A partir d'une revue systématique de la littérature (21 articles), cette étude analyse les séquelles physiques liées aux traitements anticancéreux chez des patients ayant survécu au moins 5 ans à un cancer pédiatrique dans les pays à faible et moyen revenu

Physical late effects of treatment among survivors of childhood cancer in low- and middle-income countries: a systematic review

Wong, Kevin A. ; Moskalewicz, Alexandra ; Nathan, Paul C. ; Gupta, Sumit ; Denburg, Avram

Purpose: Physical late effects of treatment are well-documented among childhood cancer survivors in high-income countries, but whether prevalence and risk factors are comparable in low- and middle-income countries (LMICs) is unclear. We conducted a systematic review to assess physical late effect outcomes among childhood cancer survivors in LMICs. Methods: Five health sciences databases were searched from inception to November 2022 in all languages. We included observational studies conducted [...]

Menée à partir de données 1990-2021 du registre néerlandais des cancers portant sur 4 273 patients atteints d'un carcinome épidermoïde de l'anus (âge médian : 63 ans), cette étude analyse l'évolution de l'incidence de la maladie et des traitements

Trends in epidemiology and primary treatment of anal squamous cell carcinoma in the Netherlands (1990–2021)

Ho, Vincent K. Y. ; Deijen, Charlotte L. ; Hemmes, Birgit ; van Erning, Felice N. ; Snaebjornsson, Petur ; van Triest, Baukelien ; Grotenhuis, Brechtje A.

A rapid increase in the incidence of anal squamous cell carcinoma (SCC) was reported in several countries over the past decades. This study assessed trends in epidemiology and primary treatment over a 32-year period (1990–2021) using the Netherlands Cancer Registry. The study population included 4273 patients, 44.2% male and 55.8% female (median age 63 years). The age-standardised incidence rate (European Standardised Rate, ESR) increased from 0.5 to 1.6 per 100,000, which entailed an average [...]

Menée en Chine, cette étude estime, pour les années 2000, 2005, 2010, 2015 et 2020 et à l'aide de trois méthodes, la part des décès par cancer du poumon attribuable au tabagisme

Estimating smoking-attributable lung cancer mortality in Chinese adults from 2000 to 2020: a comparison of three methods

Ai, Feiling ; Zhao, Jian ; Yang, Wenyi ; Wan, Xia

Background: Smoking is a significant public health concern in China and a leading cause of lung cancer deaths among adults. This study aims to employ three methods to estimate smoking-attributable lung cancer mortality among Chinese adults from 2000 to 2020. Methods: Population attributable fractions (PAFs) of lung cancer deaths caused by smoking were estimated using lagged smoking prevalence, Peto-Lopez, and dose–response relationship methods, separately. Smoking exposure was obtained from [...]

Menée à partir de données portant sur 1 099 patientes atteintes d'un cancer du sein HER2/neu+ (durée médiane de suivi : 78,6 mois), cette étude rétrospective analyse la survie sans récidive et la survie globale en fonction de la présence de mutations constitutionnelles au niveau des gènes BRCA (73 cas)

Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations

Akkoc Mustafayev, Fatma Nihan ; Shukla, Mihir Amitabh ; Lanier, Amanda ; Milton, Denai R. ; Gutierrez, Angelica M. ; Gruschkus, Stephen K. ; Lewis, John E. ; Murthy, Rashmi K. ; Arun, Banu K.

Background: Breast cancer (BC) with germline BRCA1/2 mutations and their association with triple-negative BC has been thoroughly investigated. However, some carriers of BRCA1/2 mutations have human epidermal growth factor receptor 2 (HER2/neu)-positive BC, which has a different targeted therapy approach, and data are scarce for this patient population. The authors sought to characterize the clinical characteristics and outcomes of patients with HER2/neu-positive BC who had germline BRCA1/2 [...]

Menée à partir de données portant sur 237 patientes ménopausées atteintes d'un cancer du sein de stade précoce (âge médian : 61 ans), cette étude de cohorte prospective analyse l'association entre la masse grasse corporelle, mesurée à l'aide de l'absorptiométrie par rayons X en double énergie (DXA), et la progression de fractures vertébrales associées aux inhibiteurs de l'aromatase et au dénosumab

Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer

Cosentini, Deborah ; Pedersini, Rebecca ; Di Mauro, Pierluigi ; Zamparini, Manuel ; Schivardi, Greta ; Rinaudo, Luca ; Di Meo, Nunzia ; Del Barba, Andrea ; Cappelli, Carlo ; Laganà, Marta ; Alberti, Andrea ; Baronchelli, Maria ; Guerci, Greta ; Laini, Lara ; Grisanti, Salvatore ; Simoncini, Edda Lucia ; Farina, Davide ; Mazziotti, Gherardo ; Berruti, Alfredo ; Bone Health Group of the ASST Spedali Civili, Brescia

Importance : Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment with bone-active drugs. Risk factors for fractures in patients receiving AIs and denosumab have not been explored to date. Objectives : To evaluate whether an association exists between dual x-ray absorptiometry (DXA)–measured fat body mass (FBM) and vertebral fracture (VF) progression in postmenopausal women with EBC undergoing adjuvant therapy with AIs [...]

Menée à partir de données portant sur 90 jeunes adultes atteints d'un sarcome traité par chimiothérapie (âge : 16-40 ans) et sur 30 témoins, cette étude analyse leurs déficiences cognitives et neuropsychologiques auto-déclarées

Patient-reported cognitive impairments and objective neuropsychological deficits in young sarcoma patients undergoing chemotherapy and its comparison to healthy controls: A tertiary health care study from India

Vayyat, Shyam ; Revand, Ravindran ; Rastogi, Sameer ; Sharma, Ratna ; Kaur, Simran

The study aims to investigate the patient-reported cognitive deficits and objective neuropsychological functions in younger adult (YA) sarcoma patients (16–40 years of age). Ninety patients and 30 age-matched healthy controls from a single tertiary healthcare hospital, were recruited into four groups: Pre-chemotherapy (Pre Cx), During chemotherapy (During Cx), Post-chemotherapy (Post Cx) and Controls. Neurocognitive functions were assessed subjectively using FACT-Cog v3 questionnaire; [...]

Menée aux Etats-Unis, cette étude estime, pour la période 2022-2052, les économies générées par l'arrêt des inhibiteurs de tyrosine kinase, après obtention d'une réponse moléculaire profonde, chez les patients atteints d'une leucémie myéloïde chronique

Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia

Winn, Aaron N. ; Atallah, Ehab ; Cortes, Jorge ; Deininger, Michael W. N. ; Kota, Vamsi ; Larson, Richard A. ; Moore, Joseph O. ; Mauro, Michael J. ; Oehler, Vivian G. ; Pinilla-Ibarz, Javier ; Radich, Jerald P. ; Shah, Neil P. ; Thompson, James E. ; Flynn, Kathryn E.

Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response using tyrosine kinase inhibitors (TKIs) can safely attempt to stop their use. As these medications are very costly, this change in treatment protocols may result in large savings.To estimate future savings from attempting to stop TKI use among patients with CML who have deep molecular response.A microsimulation model was developed for this decision analytical modeling study to estimate costs for US adults [...]

Menée aux Etats-Unis, cette étude évalue le rapport coût-efficacité de l'olaparib en traitement adjuvant chez des patientes atteintes d'un cancer du sein et présentant des mutations constitutionnelles au niveau des gènes BRCA

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations

Zettler, Christina M. ; De Silva, Dilanka L. ; Blinder, Victoria S. ; Robson, Mark E. ; Elkin, Elena B.

The OlympiA trial found that 1 year of adjuvant olaparib therapy can improve distant disease-free survival and overall survival from early-stage breast cancer in patients with a germline BRCA1/2 mutation. However, olaparib, an oral poly-adenosine diphosphate ribose polymerase inhibitor, is estimated to cost approximately $14 000 per month in the US.To estimate the incremental cost-effectiveness of adjuvant olaparib compared with no olaparib in eligible patients.In an economic evaluation from a [...]

Menée aux Etats-Unis auprès de 240 aidants de patients atteints d'un cancer du pancréas ou d'un cancer péri-ampullaire, cette étude analyse la qualité de la communication avec l'équipe médicale après la pancréatectomie puis évalue l'impact de ces échanges sur l'état de santé du patient (réadmissions hospitalières, restrictions dans les activités quotidiennes)

Caregiver-reported quality of communication in pancreatic and periampullary cancer

Fong, Zhi Ven ; Teinor, Jonathan ; Engineer, Lilly ; Yeo, Theresa P. ; Rinaldi, Dee ; Greer, Jonathan B. ; Lavu, Harish ; Qadan, Motaz ; Johnston, Fabian M. ; Ferrone, Cristina R. ; Chang, David C. ; Yeo, Charles J. ; Wolfgang, Christopher L. ; Warshaw, Andrew L. ; Lillemoe, Keith D. ; Castillo, Carlos Fernandez-del ; Weiss, Matthew J. ; Wu, Albert W. ; Wolff, Jennifer L.

Background Communication between caregivers and clinical team members is critical for transitional care, but its quality and potential impact on outcomes are not well understood. This study reports on caregiver-reported quality of communication with clinical team members in the postpancreatectomy period and examines associations of these reports with patient and caregiver outcomes. Methods Caregivers of patients with pancreatic and periampullary malignancies who had undergone pancreatectomy [...]

Cet article fait le point sur l'organisation des soins de l'après-cancer chez les adolescents et jeunes adultes (âge : 15-39 ans)

Health Care Transitions Among Adolescents and Young Adults With Cancer

Matthew J. Ehrhardt ; Danielle Novetsky Friedman ; Melissa M. Hudson

Survivors of adolescent and young adult (AYA) cancers, defined as individuals diagnosed with a primary malignancy between age 15 and 39 years, are a growing population with unique developmental, psychosocial, and health-related needs. These individuals are at excess risk of developing a wide range of chronic comorbidities compared with the general population and, therefore, require lifelong, risk-based, survivorship care to optimize long-term health outcomes. The health care needs of survivors [...]